Go to Content

LinqMed Inc.

LinqMed Inc. logo

As of February 2024

City Year of Establishment Founder
Chiba 2022 Yukie Yoshii, Hiroaki Kurihara, Hiroki Matsumoto, Atsuo Waki
Partner VC Latest round of Fundraising Valuation
DBJ Capital Co., Ltd. Series A Non-Disclosure

  • Contact Information : +81-3-6661-7661
  • linqmed@linqmed.co.jp
  • Website : a new window will openLinqMed Inc.

Program name

Deep-Tech Startups Support Program

Research theme

Development of the drug discovery platform based on 64Cu to expedite the R&D of new-generation drugs

Business Plan

In this project, a large-scale production of 64Cu will be developed. 64Cu is a unique radioisotope that emits radiation for diagnostic and therapeutic purposes and that easily binds to a variety of molecules. This project will establish Japan's original drug discovery support platform that can rapidly develop "visible" cancer treatments using 64Cu as new-generation drugs. This platform will create a new fundamental for the drug industry.

Research Outline

During this project period, we will collaborate with some companies to establish a drug discovery support platform based on 64Cu. Through this, we will develop a large-scale RI production technology that will take on the challenge of creating the next generation pharmaceutical industry infrastructure, and aim to solve economic and social issues.

(1) Establishment of a large-scale production technology of 64Cu

(2) Establishment of manufacturing technology for 64Cu with high specific radioactivity

(3) Long-term stabilization of 64Cu pharmaceuticals

Phase Business Area/Field Research Period Research Grant Amount
PCA Healthcare 2023~2025FY JPY 1,000 million

Last Updated : April 30, 2024